Abstract
Aim: The aim of this study was to evaluate the efficacy of solid lipid nanoparticles of berberine against doxorubicin-induced cardiotoxicity.
Background: Berberine (Ber) is cardioprotective, but its oral bioavailability is low, and its effect on chemotherapy-induced cardiotoxicity has not been studied.
Objective: Solid lipid nanoparticles (SLNs) of berberine chloride were prepared, characterized and evaluated in vitro against doxorubicin-induced cardiomyocyte injury.
Methods: Berberine-loaded SLNs (Ber-SLNs) were synthesized using the water-in-oil microemulsion technique with tripalmitin, Tween 80 and poloxamer 407. Ber-SLNs were evaluated for preventive effect against toxicity of doxorubicin in H9c2 cells. The culture was pre-treated (24 h) with Ber (10 μM) and Ber-SLNs (1 and 10 μM), and 1 μM of doxorubicin (Dox) was added for 3 h. The cell viability assay (MTT (3-(4,5-Dimethylthiazol-2-yl-2,5-diphenyltetrazolium bromide) and LDH (Lactate dehydrogenase)), levels of Creatine kinase-MB (CK-MB), Nitrite, MDA (Malondialdehyde), ROS (Reactive oxygen species) generation, and apoptotic DNA (Deoxyribonucleic acid) content were assessed.
Results: Ber-SLNs had a mean particle size of 13.12±1.188 nm, the zeta potential of -1.05 ± 0.08 mV, poly-dispersity index (PDI) of 0.317 ± 0.05 and entrapment efficiency of 50 ± 4.8%. Cell viability was 81 ± 0.17% for Ber-SLNs (10 μM) and 73.22 ± 0.83% for Ber (10 μM) treated cells in the MTT assay. Percentage cytotoxicity calculated from LDH release was 58.91 ± 0.54% after Dox, 40.3 ± 1.3% with Ber (10 μM) and 40.7 ± 1.3% with Ber-SLNs (1 μM) (p<0.001). Inflammation and oxidative stress markers were lower with Ber and Ber-SLNs. Attenuation of ROS generation and apoptosis of cardiomyocytes were noted on fluorescence microscopy.
Conclusion: Ber SLNs effectively prevented doxorubicin-induced inflammation and oxidative stress in rat cardiomyocytes. The results demonstrate that microemulsion is a simple and costeffective technique to prepare Ber-SLNs, and may be considered as a drug delivery vehicle for berberine.
Keywords: Chemotherapy-induced cardiotoxicity, berberine, doxorubicin, H9c2 cells, microemulsion, solid lipid nanoparticles.
[http://dx.doi.org/10.1016/j.atherosclerosis.2018.07.014] [PMID: 30055326]
[http://dx.doi.org/10.1093/jnci/djaa096] [PMID: 32634223]
[http://dx.doi.org/10.1136/heartjnl-2017-312103] [PMID: 29217634]
[http://dx.doi.org/10.1038/s41467-020-15639-5] [PMID: 32332714]
[http://dx.doi.org/10.1093/eurheartj/ehw211] [PMID: 27567406]
[http://dx.doi.org/10.3390/ijms20194928] [PMID: 31590338]
[http://dx.doi.org/10.1080/10412905.2019.1577305]
[http://dx.doi.org/10.1007/s11694-014-9171-x]
[PMID: 30151294]
[http://dx.doi.org/10.1016/j.jpba.2018.02.012] [PMID: 29438868]
[http://dx.doi.org/10.1155/2018/2581031] [PMID: 30224925]
[http://dx.doi.org/10.1002/ptr.6252] [PMID: 30637820]
[http://dx.doi.org/10.1517/13543776.2016.1118060]
[http://dx.doi.org/10.1038/s41598-017-11860-3] [PMID: 28900305]
[http://dx.doi.org/10.1016/j.jep.2009.08.009] [PMID: 19686830]
[http://dx.doi.org/10.1155/2018/5164314] [PMID: 29849710]
[http://dx.doi.org/10.1186/s12865-020-00358-9] [PMID: 32429849]
[http://dx.doi.org/10.1016/j.molimm.2015.07.013] [PMID: 26224047]
[http://dx.doi.org/10.1186/s12944-016-0383-4] [PMID: 27938388]
[http://dx.doi.org/10.1038/aps.2016.125] [PMID: 27917872]
[http://dx.doi.org/10.3389/fcimb.2020.588517] [PMID: 33680978]
[http://dx.doi.org/10.3389/fphar.2018.00214] [PMID: 29618977]
[http://dx.doi.org/10.3389/fmolb.2018.00021] [PMID: 29616225]
[http://dx.doi.org/10.2147/DDDT.S156123] [PMID: 29491706]
[http://dx.doi.org/10.1155/2018/7173920] [PMID: 30057809]
[http://dx.doi.org/10.3892/mmr.2017.6147] [PMID: 28138704]
[http://dx.doi.org/10.1016/j.metabol.2013.02.007] [PMID: 23537779]
[http://dx.doi.org/10.1016/j.biopha.2017.07.051] [PMID: 28738542]
[http://dx.doi.org/10.1016/0014-2999(87)90090-2] [PMID: 3123257]
[http://dx.doi.org/10.1006/abio.1993.1002] [PMID: 8434778]
[http://dx.doi.org/10.1002/cplu.202000496] [PMID: 32864902]
[http://dx.doi.org/10.1016/j.cis.2006.05.014] [PMID: 16843424]
[PMID: 25711493]
[http://dx.doi.org/10.3390/nano9010018] [PMID: 30583592]
[PMID: 18717486]
[http://dx.doi.org/10.1002/jps.20590] [PMID: 16570303]
[http://dx.doi.org/10.1080/10837450600561265] [PMID: 16749527]
[http://dx.doi.org/10.1016/j.colsurfb.2015.01.055] [PMID: 25734967]
[http://dx.doi.org/10.1023/A:1016030812272] [PMID: 8932438]
[http://dx.doi.org/10.2174/156720106777731118] [PMID: 16848728]
[http://dx.doi.org/10.1615/CritRevTherDrugCarrierSyst.2014010663] [PMID: 25271559]
[http://dx.doi.org/10.1038/s41598-020-75662-w] [PMID: 33122763]
[http://dx.doi.org/10.1124/pr.56.2.6] [PMID: 15169927]
[http://dx.doi.org/10.1016/j.ejphar.2014.01.065] [PMID: 24509133]
[http://dx.doi.org/10.1016/j.pcad.2006.10.002] [PMID: 17329180]
[http://dx.doi.org/10.1161/CIRCRESAHA.116.309326] [PMID: 28209797]
[http://dx.doi.org/10.1155/2021/6628957] [PMID: 33824696]
[PMID: 15375752]
[http://dx.doi.org/10.1016/S1734-1140(09)70018-0] [PMID: 19307704]
[http://dx.doi.org/10.1186/s40360-017-0184-z] [PMID: 29321061]
[http://dx.doi.org/10.1073/pnas.1821022116] [PMID: 30692261]